Patents by Inventor Christian Josef Wiedermann

Christian Josef Wiedermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations
    Patent number: 7803569
    Abstract: An arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: September 28, 2010
    Assignee: CSL Behring GmbH
    Inventors: Stefan Kiechl, Johann Willeit, Christian Josef Wiedermann, Juergen Roemisch, Thomas Weimer, Annette Feussner, Hans-Arnold Stoehr, Volker Doersam, Wiegand Lang, Margret Becker, Claudia Nerlich, Gudrun Muth-Naumann, Bernd Knoblauch
  • Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
    Patent number: 7153679
    Abstract: A novel arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII-activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: December 26, 2006
    Assignee: Aventis Behring GmbH
    Inventors: Stefan Kiechl, Johann Willeit, Christian Josef Wiedermann, Juergen Roemisch, Thomas Weimer, Annette Feussner, Hans-Arnold Stoehr, Volker Doersam, Wiegand Lang, Margret Becker, Claudia Nerlich, Gudrun Muth-Naumann, Bernd Knoblauch
  • Use of antithrombin III for the prophylaxis and therapy of diseases
    Publication number: 20040229795
    Abstract: The use of antithrombin III for the prophylaxis and therapy of oncological diseases and diseases accompanying neovascularization, immune complex-mediated and autoimmune diseases, viral infections, fibrotic and granulomatous diseases, allergic diseases, degenerative diseases of the nervous system and arteriosclerosis and also acute inflammatory diseases and trauma is described.
    Type: Application
    Filed: February 25, 2004
    Publication date: November 18, 2004
    Applicant: Aventis Behring GmbH
    Inventors: Juergen Roemisch, Harald Stauss, Christian Josef Wiedermann
  • Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
    Publication number: 20040009543
    Abstract: A novel arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII-activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.
    Type: Application
    Filed: March 19, 2003
    Publication date: January 15, 2004
    Inventors: Stefan Kiechl, Johann Willeit, Christian Josef Wiedermann, Juergen Roemisch, Thomas Weimer, Annette Feussner, Hans-Arnold Stoehr, Volker Doersam, Wiegand Lang, Margret Becker, Claudia Nerlich, Gudrun Muth-Naumann, Bernd Knoblauch
  • Antithrombin III for disorders caused by angiogenesis
    Publication number: 20020119143
    Abstract: The use of active antithrombin III which has thrombin-inhibitory properties and affinity for heparin for the prophylaxis and treatment of disorders caused by pathological angiogenesis or arteriogenesis, is described.
    Type: Application
    Filed: January 16, 2002
    Publication date: August 29, 2002
    Inventors: C. Jane Robinson, Elaine Gray, Christian Josef Wiedermann, Juergen Roemisch, Harald Stauss